Sonidegib
Odomzo® (sonidegib) was approved by the FDA in 2015. It is used to treat locally advanced basal cell carcinomaCancer of epithelial cells, the cells that cover the outside and inside of body surfaces. This is the most common form of cancer. (BCC) in patients who cannot be treated with surgery or radiationIn cancer biology: A cancer treatment in which high energy beams are used to kill cancer cells. Radiation can also cause genetic damage that can lead to cancer. As an example, skin cancer is believed to be greatly increased by exposure to ultraviolet (UV) radiation from the sun. therapy and in patients whose BCC has recurred after surgery or radiation therapy.
Sonidegib (Odomzo®) is a Hedgehog pathway inhibitor. Sonidegib inhibits the Hedgehog pathway by binding to and inhibiting Smoothened, a transmembrane proteinA protein that spans the entire thickness of a membrane and has portions exposed on both sides. Often, transmembrane proteins located in the plasma membrane are involved in communicating messages from outside the cell to the inside, allowing the cell to change its behavior. Examples include growth factor receptors and proteins involved in cell to cell adhesion. involved in Hedgehog signaling. The hedgehog pathway is overactive is basal cell carcinomaCancer of epithelial cells, the cells that cover the outside and inside of body surfaces. This is the most common form of cancer. (BCC), so suppression of this pathway may reduce and stop BCC growth.1
The diagram above shows the 3D molecular structure of Sonidegib.
Most common side effects include: muscle spasms, alopecia, dysgeusia, fatigue, nausea, musculoskeletal pain, diarrhea, weight loss, appetite loss, myalgia, abdominal pain, headache, pain, vomiting, and pruritus.1
Top